Common Drug Could Eliminate Back Pain

White pills and syringes arranged on a reflective surface

A common osteoporosis drug might halt chronic back pain by blocking rogue nerves at their spinal source, offering hope beyond addictive opioids.

Story Highlights

Parathyroid hormone (PTH) triggers osteoblasts to produce Slit3 protein, repelling pain-sensing nerves in degenerating spines.
Mouse models across aging, instability, and genetic defects showed denser bones, fewer nerves, and reduced pain responses after PTH treatment.
Johns Hopkins researchers published findings January 22, 2026, in Bone Research, explaining prior unexplained pain relief in osteoporosis patients.
Potential to repurpose FDA-approved teriparatide for low back pain, the top global disability cause affecting 80% of adults.

Mechanism of PTH in Blocking Spinal Nerve Invasion

Dr. Janet L. Crane’s team at Johns Hopkins injected PTH daily into mice for two weeks to two months. PTH activated FoxA2 transcription factor in osteoblasts. These cells then produced Slit3 protein. Slit3 repelled abnormal nociceptor growth into damaged vertebral endplates. Knocking out Slit3 erased all benefits, proving causality. Treated spines displayed denser structures and lower PGP9.5 and CGRP nerve markers.

Scientists discover hormone that may stop chronic back pain at its source

A new study suggests a widely used bone hormone could help relieve chronic back pain in an unexpected way. Instead of just strengthening bone, it appears to stop pain-sensing nerves from growing into…

— The Something Guy 🇿🇦 (@thesomethingguy) March 24, 2026

Three Mouse Models Validate Robust Findings

Researchers tested aging mice, surgically destabilized spines, and genetic disc degeneration models. All replicated human-like low back pain from ectopic nerve sprouting. PTH restored bone integrity and slashed pain sensitivity to pressure, heat, and movement. Behavioral assays confirmed mice withdrew less from stimuli. Advanced imaging pinpointed reduced innervation. This multi-model approach bolsters reliability over single-model studies.

Historical PTH Use and Unexplained Pain Relief

Parathyroid glands produce PTH to balance calcium and remodel bone. Teriparatide (Forteo), approved in 2002, builds bone density in osteoporosis patients. Many reported back pain easing without clear reason. Prior research noted benefits but missed mechanisms. Slit/Robo pathways, known for guiding fetal nerves, now apply to adult spines. This bridges observation to science.

Johns Hopkins Team Drives Breakthrough

Weixin Zhang led experiments under Crane’s direction, with co-authors like Arryn D. Otte and Xu Cao contributing imaging and genetics expertise. The Center for Musculoskeletal Research provided facilities. No conflicts emerged; NIH funding likely supported rigor. Crane stated PTH reduces aberrant innervation, paving clinical trial paths. Journal editors at Nature’s Bone Research peer-reviewed rigorously.

Implications for Patients and Medicine

Chronic low back pain disables millions yearly, costing $100 billion in U.S. care. Opioids and surgery falter long-term. PTH repurposing offers disease modification over symptoms. Osteoporosis patients gain mechanistic insight. Spine specialists eye Slit3 biotech. Human trials needed bridge preclinical gap.